# Comprehensively analysis of IL33 in hepatocellular carcinoma prognosis, immune microenvironment and biological role

**Authors:** Lifang Wei, Ping He, Zhongqiu Tan, Cheng Lin, Zhongheng Wei

PMC · DOI: 10.1111/jcmm.18468 · Journal of Cellular and Molecular Medicine · 2024-06-24

## TL;DR

This study explores the role of IL33 in liver cancer, showing it is linked to patient survival and cancer development.

## Contribution

The study reveals IL33's differential expression in HCC and its correlations with survival and immune microenvironment features.

## Key findings

- IL33 is differentially expressed in hepatocellular carcinoma and is primarily expressed in endothelial cells.
- Higher IL33 expression correlates with patient survival, suggesting potential prognostic value.
- IL33 is associated with immune cell activity and processes like angiogenesis and inflammation in cancer.

## Abstract

IL33 plays an important role in cancer. However, the role of liver cancer remains unclear. Open‐accessed data was obtained from the Cancer Genome Atlas, Xena, and TISCH databases. Different algorithms and R packages are used to perform various analyses. Here, in our comprehensive study on IL33 in HCC, we observed its differential expression across cancers, implicating its role in cancer development. The single‐cell analysis highlighted its primary expression in endothelial cells, unveiling correlations within the HCC microenvironment. Also, the expression level of IL33 was correlated with patients survival, emphasizing its potential prognostic value. Biological enrichment analyses revealed associations with stem cell division, angiogenesis, and inflammatory response. IL33's impact on the immune microenvironment showcased correlations with diverse immune cells. Genomic features and drug sensitivity analyses provided insights into IL33's broader implications. In a pan‐cancer context, IL33 emerged as a potential tumour‐inhibitor, influencing immune‐related molecules. This study significantly advances our understanding of IL33 in cancer biology. IL33 exhibited differential expression across cancers, particularly in endothelial cells within the HCC microenvironment. IL33 is correlated with the survival of HCC patients, indicating potential prognostic value and highlighting its broader implications in cancer biology.

## Linked entities

- **Genes:** IL33 (interleukin 33) [NCBI Gene 90865]
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), cancer (MONDO:0004992)

## Full-text entities

- **Genes:** IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}
- **Diseases:** HCC (MESH:D006528), Cancer (MESH:D009369), inflammatory (MESH:D007249)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11196832/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11196832/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC11196832/full.md

---
Source: https://tomesphere.com/paper/PMC11196832